Skip to content

Study · Case report or series · n = 1 · 2025

8 results

Weight Management in a Patient With Smith-Magenis Syndrome: The Role of GLP-1 Receptor Agonists.

Correia JC, Frayling T, Pataky Z

JCEM case reports29 May 2025Cited by 1 (Europe PMC)

PMID40443456 (opens in a new tab)PMCIDPMC12119458 (opens in a new tab)DOI10.1210/jcemcr/luaf094 (opens in a new tab)PepBankPUB-40443456
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

Smith-Magenis syndrome (SMS) is a rare genetic disorder characterized by intellectual disability, behavioral challenges, sleep disturbances, and obesity. Managing obesity in SMS is complex due to the behavioral dysregulation. This case involves a patient with SMS who experienced significant weight gain from early in childhood, developing complications such as type 2 diabetes, dyslipidemia, and steatotic liver disease. Initial management with lifestyle changes was insufficient, leading to progressive weight gain. At age 18 years, subcutaneous semaglutide was introduced, resulting in marked improvements in impulsivity, food cravings, and weight control. However, because of a global shortage of this medication, at age 21 years, she was switched to the oral formulation of semaglutide, which led to a relapse in violent behavior, increased food intake, and weight regain. When subcutaneous semaglutide became available again, it was reinstated, stabilizing her weight and behavior. This case underscores the potential of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in managing both obesity and behavioral symptoms in SMS. While injectable GLP-1 RAs show promise, further research is needed to determine why they may be more effective than oral formulations. Further studies are needed to confirm the effectiveness of GLP-1 RAs and the dosage and explore alternative treatments for long-term obesity management in genetic syndromes.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a patient with Smith-Magenis syndrome and obesity, subcutaneous semaglutide was followed by marked improvement in impulsivity.

    In plain wordsIn one patient with Smith-Magenis syndrome, injected semaglutide was followed by less impulsive behavior.

    Peptide
    Semaglutide
    Outcome
    DecreaseImpulsivity on subcutaneous semaglutide
    Study

    n = 1

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    At age 18 years, subcutaneous semaglutide was introduced, resulting in marked improvements in impulsivity, food cravings, and weight control.
    1 context sentence
    Summary · context
    This case involves a patient with SMS who experienced significant weight gain from early in childhood, developing complications such as type 2 diabetes, dyslipidemia, and steatotic liver disease.
  2. 02HumanCase report or seriesEfficacy outcome

    In a patient with Smith-Magenis syndrome and obesity, subcutaneous semaglutide was followed by marked improvement in food cravings.

    In plain wordsIn one patient with Smith-Magenis syndrome, injected semaglutide was followed by fewer food cravings.

    Peptide
    Semaglutide
    Outcome
    DecreaseFood cravings on subcutaneous semaglutide
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    At age 18 years, subcutaneous semaglutide was introduced, resulting in marked improvements in impulsivity, food cravings, and weight control.
    1 context sentence
    Summary · context
    This case involves a patient with SMS who experienced significant weight gain from early in childhood, developing complications such as type 2 diabetes, dyslipidemia, and steatotic liver disease.
  3. 03HumanCase report or seriesEfficacy outcome

    In a patient with Smith-Magenis syndrome and obesity, subcutaneous semaglutide was followed by marked improvement in weight control.

    In plain wordsIn one patient with Smith-Magenis syndrome, injected semaglutide was followed by better weight control.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedWeight control on subcutaneous semaglutide
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    At age 18 years, subcutaneous semaglutide was introduced, resulting in marked improvements in impulsivity, food cravings, and weight control.
    1 context sentence
    Summary · context
    This case involves a patient with SMS who experienced significant weight gain from early in childhood, developing complications such as type 2 diabetes, dyslipidemia, and steatotic liver disease.
  4. 04HumanCase report or seriesEfficacy outcome

    In a patient with Smith-Magenis syndrome, switching from subcutaneous to oral semaglutide was followed by a relapse in violent behavior.

    In plain wordsIn one patient with Smith-Magenis syndrome, switching from injected to oral semaglutide was followed by a return of violent behavior.

    Peptide
    Semaglutide
    Outcome
    IncreaseViolent behavior after switch to oral semaglutide
    Study

    n = 1

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    However, because of a global shortage of this medication, at age 21 years, she was switched to the oral formulation of semaglutide, which led to a relapse in violent behavior, increased food intake, and weight regain.
    1 context sentence
    Summary · context
    This case involves a patient with SMS who experienced significant weight gain from early in childhood, developing complications such as type 2 diabetes, dyslipidemia, and steatotic liver disease.
  5. 05HumanCase report or seriesEfficacy outcome

    In a patient with Smith-Magenis syndrome, switching from subcutaneous to oral semaglutide was followed by increased food intake.

    In plain wordsIn one patient with Smith-Magenis syndrome, switching from injected to oral semaglutide was followed by eating more.

    Peptide
    Semaglutide
    Outcome
    IncreaseFood intake after switch to oral semaglutide
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    However, because of a global shortage of this medication, at age 21 years, she was switched to the oral formulation of semaglutide, which led to a relapse in violent behavior, increased food intake, and weight regain.
    1 context sentence
    Summary · context
    This case involves a patient with SMS who experienced significant weight gain from early in childhood, developing complications such as type 2 diabetes, dyslipidemia, and steatotic liver disease.
  6. 06HumanCase report or seriesEfficacy outcome

    In a patient with Smith-Magenis syndrome, switching from subcutaneous to oral semaglutide was followed by weight regain.

    In plain wordsIn one patient with Smith-Magenis syndrome, switching from injected to oral semaglutide was followed by weight regain.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight after switch to oral semaglutide
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    However, because of a global shortage of this medication, at age 21 years, she was switched to the oral formulation of semaglutide, which led to a relapse in violent behavior, increased food intake, and weight regain.
    1 context sentence
    Summary · context
    This case involves a patient with SMS who experienced significant weight gain from early in childhood, developing complications such as type 2 diabetes, dyslipidemia, and steatotic liver disease.
  7. 07HumanCase report or seriesEfficacy outcome

    In a patient with Smith-Magenis syndrome, reinstating subcutaneous semaglutide was followed by stable weight.

    In plain wordsIn one patient with Smith-Magenis syndrome, going back to injected semaglutide was followed by stable weight.

    Peptide
    Semaglutide
    Outcome
    No significant changeWeight after reinstating subcutaneous semaglutide
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    When subcutaneous semaglutide became available again, it was reinstated, stabilizing her weight and behavior.
    1 context sentence
    Summary · context
    This case involves a patient with SMS who experienced significant weight gain from early in childhood, developing complications such as type 2 diabetes, dyslipidemia, and steatotic liver disease.
  8. 08HumanCase report or seriesEfficacy outcome

    In a patient with Smith-Magenis syndrome, reinstating subcutaneous semaglutide was followed by stable behavior.

    In plain wordsIn one patient with Smith-Magenis syndrome, going back to injected semaglutide was followed by stable behavior.

    Peptide
    Semaglutide
    Outcome
    No significant changeBehavior after reinstating subcutaneous semaglutide
    Study

    n = 1

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    When subcutaneous semaglutide became available again, it was reinstated, stabilizing her weight and behavior.
    1 context sentence
    Summary · context
    This case involves a patient with SMS who experienced significant weight gain from early in childhood, developing complications such as type 2 diabetes, dyslipidemia, and steatotic liver disease.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.